Isocitrate dehydrogenase-1 and isocitrate dehydrogenase-2 (IDH1 and IDH2) encode enzymes that convert isocitrate to a-ketoglutarate (a-KG). IDH mutations are common in some cancers and currently known IDH mutations affect three specific arginine residues: R132 (IDH1), R172 (IDH2) and R140 (IDH2). The R172 of IDH1 is homologous to the R132 of IDH2: both are located at the active catalytic sites of the enzymes. IDH1 and IDH2 mutations result in reduced synthesis of a-KG and an acquired ability to convert a-KG to 2-hydroxyglutarate. The latter is believed to be a competitive inhibitor of a-KG-dependent enzymes, including histone demethylases and the Ten-Eleven Translocation family of 5-methlycytosine hydroxylases, thus leading to altered histone and DNA methylation.
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IDH1R132 and IDH2R172 mutations are most prevalent in low-grade gliomas and secondary glioblastomas (mutational frequency B70% and B5%, respectively), but not IDH2R140 mutations. 2, 3 In contrast, mutations affecting all three IDH arginine residues have been described in myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and MDS/MPN. 4 In general, IDH mutational frequencies in myeloid neoplasms are substantially lower than those seen in low-grade gliomas. In both AML and chronic myeloid neoplasms, the incidences of IDH2R140 (5 --10%) and IDH1R132 (5 --10%) mutations are similar, but IDH2R172 mutations are less frequent. 5 --7 CCDC26 is a retinoic acid-dependent modulator of myeloid cell differentiation and death.
8 CCDC26 maps to chromosome 8q24.21, and germline polymorphisms in the gene have been associated with low-grade gliomas. 9 We and others recently examined the distribution of these disease-risk alleles in IDH-mutated and IDH-unmutated glioma and found significantly different odds ratios (ORs); 10,11 among three CCDC26 SNPs, the largest OR for IDH1-positive glioblastoma samples from the Mayo Clinic was 4.18 (95% CI, 1.27 --13.78; P ¼ 0.02), whereas for IDH1-negative glioblastoma all the ORs were p1.00 (P ¼ NS). These observations suggested that CCDC26 glioma-risk alleles are associated with the development of IDH1-positive glioblastoma and we, therefore, hypothesized that the same might be true for IDH1-mutated myeloid malignancies.
In order to test our hypothesis of an association between CCDC26 polymorphisms and IDH1-mutated myeloid malignancies, we genotyped 72 IDH-mutated and 153 IDH-unmutated patients with acute or chronic myeloid neoplasms for three CCDC26 SNPs (rs10464870, rs891835 and rs4295627) that have previously been shown to be associated with low-grade glioma.
9,10 Our 72 IDH-mutated patients included 18 IDH1R132-, 1 IDH2R172-and 53 IDH2R140-mutated cases. There was no significant difference in the age, gender and race distribution between the IDH-mutated and IDH-unmutated groups. The respective minor allele frequencies (MAF) were significantly different between IDH1R132 (11, 8 and 6%)-and IDH2R140 (30, 27 and 24%)-mutated cases (P ¼ 0.037, 0.040 and 0.021; OR 3.4, 3.7 and 6.1, with 95% CIs of 1.1--10.5, 1.1--13.0 and 1.3--28.9, respectively), as well as between IDH-wild-type (24, 24 and 21%) and IDH1-mutated but not between IDH-wild-type and IDH2R140-mutated cases. The MAF values in our IDH-unmutated cases were similar to those of population-based controls (data not shown).
Our observations suggest a differential distribution of CCDC26 glioma-risk alleles in IDH1-mutated myeloid malignancies compared with either their IDH2R140-mutated or IDH-unmutated counterparts. Consequently, it is possible that such differences in genomic context contributes to hitherto-seen differences in the development of mutant IDH2R140 and mutant IDH1R132/IDH2R172, in both AML 7, 12, 13 and MDS, 14 despite the similar predicted functional consequences of such mutations. A much larger number of cases is required to prove this contention and allow comparison of prognosis between IDH1-and IDH2-mutated cases that takes into account the specific CCDC26 SNP distribution. We were also intrigued by the inverse association that was displayed by CCDC26 glioma-risk alleles with IDH1-mutated myeloid malignancies (protective) versus low-grade glioma (permissive). Whether or not this is linked to the differential development of mutant IDH1 in the two diseases is currently unknown. Myeloproliferative neoplasms (MPNs) are a group of clonal disorders that arise from the transformation of hematopoietic stem cells. In 2005, several groups reported a single acquired point mutation in the Janus kinase 2 (Jak2) gene in the majority of patients with Philadelphia chromosome (Ph)-negative MPN. 1 The mutation is believed to have a critical role in the pathogenesis of these disorders, 2, 3 and it has been suggested that most patients harbor mutations (some of which remain to be identified) that potentially serve as a molecular target for selective Jak2 inhibition. 4 Although small molecule Jak2 inhibitors are entering clinical trials, their ultimate efficacy is unclear. 5 In addition to the concern of insufficient inhibition of mutated Jak2 in vivo or the emergence of resistance through activation of complementary pathways, many MPNs contain other mutational events (for example, mutation in exon12 of Mpl, 6 or the KIT D618V mutation in patients with systemic mastocytosis 7 ), and thus are not sensitive to Jak inhibitors. Therefore, the development of inhibitors to common mediators of diverse signaling pathways in this disease is very desirable.
CONFLICT OF INTEREST
One convergence point of these pathways is the transcription factor STAT5. STAT5 regulates the expression of genes controlling key events such as cell cycle progression and survival. Thus, continuous STAT5 activation drives increased expression of these genes that directly contribute to leukemogenesis. Continued STAT5 activation appears to be necessary for tumor cell survival, 8 although normal cells are generally tolerant to the loss of STAT5 function. Consequently, STAT5 is an attractive target for cancer therapy. Increasing evidence indicates that STAT5 activation is required for Jak2 V617F-mediated transformation.
9 As STAT5 is a critical mediator of the effects of Jak2 V617F, the development of drugs that inhibit this transcription factor holds promise as a treatment for MPN. Furthermore, the dual inhibition of both STAT5 and Jak2 may yield better disease control.
We previously identified the neuroleptic drug pimozide as an inhibitor of STAT5 transcriptional function in a cell-based screen.
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In the present study, we evaluated the effect of pimozide alone and in combination with a Jak2 inhibitor on the biology of myeloproliferative cell lines. We examined a model system, Ba/F3 cells that had been reconstituted with erythropoietin receptor and the mutant form of Jak2 (BAFEJ), as well as the HEL and SET2 human leukemia cell lines that endogenously express Jak2 V617F. Treatment of each cell line with pimozide led to a decrease in tyrosine phosphorylation of STAT5 (Figure 1a and data not shown). Reflecting the fact that the phosphorylation of STAT5 is mediated by activated Jak2, the Jak2 inhibitor Jak inhibitor 1 also led to decreased phosphorylation of STAT5. STAT3 phosphorylation was only minimally affected by pimozide (Figure 1a) . Thus, the principal effect of pimozide in these MPN cell lines is the inhibition of STAT5 phosphorylation.
Three lines of evidence suggest that pimozide is not functioning as a classic kinase inhibitor. First, pimozide does not inhibit Jak family kinases in an isolated in vitro kinase assays (Table 1) . Second, its pattern of inhibition of substrate phosphorylation catalyzed by extracts from Jak2 V617F-expressing cells using the PamChip tyrosine kinase microarray system (PamGene, Den Bosch, Netherlands)
11 is clearly distinct from that mediated by a Jak inhibitor (including no inhibition of the phopshorylation of the Jak2 peptide by pimozide; Figure 1b) . Pimozide did inhibit phosphorylation of a peptide derived from Jak1, though this likely occurred through an indirect mechanism. Finally, other signaling pathways downstream of Jak2, such as the phosphorylation of extracellular signal-regulated kinase mitogen-activated protein kinases (MAPK) are not inhibited by pimozide (as they are with Jak inhibitor 1) in BAFEJ and HEL cells, and actually show a small but reproducible increased activity (Figure 1c) . This finding is similar to that seen in cells transformed with BCR/ABL, 10 and may reflect a loss of a negative regulator of MAPK signaling that is STAT5 dependent.
12 Although the exact mechanism by which pimozide inhibits STAT5 phosphorylation is being elucidated, it may involve direct effects on STAT5 or on a negative regulator of STAT5 activation rather than by targeting a kinase.
Consistent with the central role of STAT5 activation in driving expression of genes underlying the malignant nature of these cells, inhibition of STAT5 phosphorylation by pimozide also led to a decrease in expression of STAT5 target genes (Figure 1d) . Significantly, these include two important pro-survival genes, Bcl-xl and Mcl1. Bcl-xl appears to be a key mediator in promoting Jak2-mediated survival in SET2 cells 13 as inhibition of Jak2 signaling blocked STAT5-mediated regulation of Bcl-xl mRNA level and reduced its protein expression. Mcl1 is also a critical survival factor in MPN cells. Specific STAT5-docking domains have a major role in inducing Mcl1 expression driven by a mutated FLT3 containing an internal tandem duplication (FLT3-ITD), a mutation found in about 20% of acute myelogenous leukemia patients, independent of JAK2 activation. 14 Given that pimozide inhibits STAT5 tyrosine phosphorylation and decreases STAT5 target genes expression, we next determined whether pimozide also affects the viability of cells with activating mutations of Jak2. Pimozide caused a dose-dependent decrease in viability of the three cell lines, with IC 50 (half maximal inhibitory concentration) values ranging from 4 mM for BAFEJ and SET2 to 10 mM for HEL cells (Figure 1e and data not shown). As expected, pimozide also inhibits survival of parental Ba/F3 cells, which are known to be dependent on STAT5.
To determine the mechanism by which pimozide decreases viable cell numbers, BAFEJ and HEL cells were treated with pimozide for 24 h, after which they were permeabilized and stained with propidium iodide followed by flow cytometric
